시장보고서

상품코드

1631117

외상 후 스트레스 장애 치료 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 인구통계별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Post-traumatic Stress Disorder Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Demographics, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2024년 12월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

외상 후 스트레스 장애 치료 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 외상 후 스트레스 장애 치료 시장 규모는 2030년까지 28억 5,000만 달러에 달할 것으로 예측됩니다.

이 시장은 2025-2030년에 걸쳐 CAGR 4.08%를 나타낼 것으로 예측됩니다. 외상 후 스트레스 장애(PTSD)의 질병 부담 증가, 연구개발에 있어서의 기술 혁신과 새로운 의약품 파이프라인, 인지도 향상을 위한 정부와 비영리 단체의 노력이 같은 영역의 성장을 증대시키는 주요 요인입니다.

PTSD의 치료로 기대되는 신약 파이프라인의 발전과 신약의 출시는 예측 기간 동안 시장 성장에 유리한 기회를 제공할 것으로 예상됩니다. 이는 Aptinyx의 NYX-783, Bionomics의 BNC210, Jazz Pharmaceuticals의 JZP150이 2상 임상 검사 중이기 때문입니다. 이에 앞서, Otsuka Pharmaceutical의 Brespiprazole과 Zoloft의 경쟁이 3상 임상 검사 중이며, 이 영역에서 제품 출시를 향해 주요 기업간에 치열한 경쟁이 벌어지고 있습니다.

COVID-19의 유행과 같은 사건은이 지역의 성장을 더욱 향상시킵니다. COVID-19의 유행이 정신 건강에 미치는 영향을 이해하기 위해 여러 연구가 실시되어 PTSD의 위험이 증가하고 치료에 대한 수요가 증가하고 있습니다. 예를 들어, 2021년 8월에 작성된 리뷰 기사 'COVID-19와 외상 후 스트레스 장애 : The Perfect'Storm' for Mental Health'''는 유행의 영향을 받은 가족과 생존자들 사이에서 PTSD의 개발 위험이 증가하고 있음을 분명히 보여줍니다.

기업은 전략적으로 신제품 개발, 규제 당국 승인, 지리적 확대로 제품 포트폴리오를 강화하기 위해 노력하고 있습니다. 예를 들어, 2022년 3월 H. Lundbeck A/S는 인도 시장에서 Vortidiftm 브랜드 이름으로 Vortioxetine을 판매하기 위한 라이선스 계약을 Sun Pharmaceutical Industries Ltd.에 부여했습니다.

외상 후 스트레스 장애 치료 시장 보고서 하이라이트

2024년에는 졸로프트(셀트랄린) 및 팍실(파록세틴)과 같은 FDA 승인 SSRI를 통해 항우울제 부문이 가장 큰 점유율을 차지했으며 예측 기간 동안에도 그 지위를 유지할 것으로 예측됩니다.
인구통계별로는 성인층에서의 질환발생률의 상승, 이 연령층의 환자의 대부분, 외상체험 증가 등의 존재로 인해 예측기간 동안 성인부문의 CAGR은 5.1%로 가장 빠르다고 추정됩니다.
유통 채널별로는 입수의 용이성, 장기 치료를 위한 재택 케어와의 적합성 등의 요인으로부터, 2024년에는 소매 약국 부문이 같은 부문을 지배했습니다.
아시아태평양은 국민 의식 증가, 가처분 소득 증가, 신흥 국가에서 PTSD의 유병률이 높기 때문에 예측 기간 동안 가장 빠른 성장을 이룰 것으로 예측됩니다.

지역 대시보드
시장 규모와 예측 동향 분석(2018-2030년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업에 의한 최근의 동향과 영향 분석
기업/경쟁의 분류
벤더 상황
- 주요 기업의 시장 점유율 분석(2024년)
- AstraZeneca
- GSK plc.
- Pfizer Inc.
- Otsuka Holdings Co., Ltd
- Aurobindo Pharma
- Merck KGaA
- Jazz Pharmaceuticals, Inc.
- Bionomics
- Eli Lilly and Company
- Viatris Inc.

KTH 25.02.28

Post-traumatic Stress Disorder Treatment Market Growth & Trends:

The global post-traumatic stress disorder treatment market size is anticipated to reach USD 2.85 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.08% from 2025 to 2030. The increasing disease burden of post-traumatic stress disorder (PTSD), innovation in R&D and emerging drug pipeline, and efforts by government and non-profit organizations to increase awareness are the key factors augmenting the space growth.

The emerging drug pipeline, thereby, expected advancement and drug launches for the treatment of PTSD, is anticipated to offer a lucrative opportunity for market growth over the forecast period. This can be attributed to the presence of Aptinyx's NYX-783, Bionomics' BNC210, and Jazz Pharmaceuticals' JZP150 under phase 2 clinical trials. Ahead of these, Otsuka Pharmaceutical's Brexpiprazole and Zoloft Combination are in phase 3 trial, creating fierce competition among key players to launch the product in the space.

Events such as the COVID-19 pandemic further support space growth. Several studies have been conducted to understand the impact of the covid 19 pandemic on mental health, increasing the risk of PTSD and rising demand for its treatment. For instance, the August 2021 review article, "COVID?19 and Post traumatic Stress Disorder: The Perfect 'Storm' for Mental Health," clearly demonstrates an increase in the risk of development of PTSD among pandemic affected families and survivors.

Companies are strategically taking initiatives that aid in developing new products, regulatory approvals, and enhancing their product portfolio with geographical expansion. For instance, in March 2022, H. Lundbeck A/S granted the license agreement to Sun Pharmaceutical Industries Ltd., for marketing and distribute of Vortioxetine under the brand name Vortidiftm in the Indian market.

Post-traumatic Stress Disorder Treatment Market Report Highlights:

In 2024, antidepressants segment accounted for the largest share and is anticipated to maintain its position over the forecast period owing to FDA approved SSRIs such as Zoloft (sertraline) and Paxil (paroxetine).
Based on demographics, adult segment is estimated to witness the fastest CAGR of 5.1% during the forecast period owing to presence of rising disorder incidence in adult group, major chunk of patients in this age group and increase in traumatic experiences.
Based on distribution channel, retail pharmacy segment dominated the space in 2024, due to factors such easy of availability, and its compatibility with homecare setting for the long term treatment.
Asia Pacific region is anticipated to experience the fastest growth over the forecast period due to an increased awareness among the population, rise in disposable income, and high disease prevalence of PTSD in developing countries.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Demographics
- 1.2.3. Distribution channel
- 1.2.4. Regional scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Drug class and demographics outlook
- 2.2.2. Distribution channel outlook
2.3. Competitive Insights

Chapter 3. Post-traumatic Stress Disorder Treatment Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. High prevalence of post-traumatic stress disorder globally
  - 3.2.1.2. Rising investment in R&D
  - 3.2.1.3. Technological advancement
- 3.2.2. Market restraint analysis
  - 3.2.2.1. Stringent regulations
  - 3.2.2.2. Side-effects associated with drug
3.3. Post-traumatic Stress Disorder Treatment Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
3.4. Pricing Analysis

Chapter 4. Post-traumatic Stress Disorder Treatment Market: Drug Class Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Post-traumatic Stress Disorder Treatment Market: Drug Class Movement Analysis
4.3. Global Post-traumatic Stress Disorder Treatment Market Estimates and Forecasts, By Drug, Class Revenue (USD Million)
4.4. Antidepressants
- 4.4.1. Antidepressants market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Anti-anxiety
- 4.5.1. Anti-anxiety market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Antipsychotics
- 4.6.1. Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Other Drug Class
- 4.7.1. Others drug class market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Post-traumatic Stress Disorder Treatment Market: Demographics Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Post-traumatic Stress Disorder Treatment Market: Demographics Movement Analysis
5.3. Global Post-traumatic Stress Disorder Treatment Market Estimates and Forecasts, By Demographics, Revenue (USD Million)
5.4. Adult
- 5.4.1. Adult market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Children
- 5.5.1. Children market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Geriatric
- 5.6.1. Geriatric market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Post-traumatic Stress Disorder Treatment Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Post-traumatic Stress Disorder Treatment Market: Distribution Channel Movement Analysis
6.3. Global Post-traumatic Stress Disorder Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
6.4. Hospitals Pharmacies
- 6.4.1. Hospitals pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Other Pharmacies
- 6.6.1. Other Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Post-traumatic Stress Disorder Treatment Market: Regional Estimates & Trend Analysis By Drug Clas, Demographics, and Distribution Channel

7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
- 7.3.1. U.S.
  - 7.3.1.1. Key country dynamics
  - 7.3.1.2. Regulatory framework/ reimbursement structure
  - 7.3.1.3. Competitive scenario
  - 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.2. Canada
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Regulatory framework/ reimbursement structure
  - 7.3.2.3. Competitive scenario
  - 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Mexico
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Regulatory framework/ reimbursement structure
  - 7.3.3.3. Competitive scenario
  - 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. France
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Regulatory framework/ reimbursement structure
  - 7.4.4.3. Competitive scenario
  - 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Regulatory framework/ reimbursement structure
  - 7.4.5.3. Competitive scenario
  - 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.6. Norway
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Regulatory framework/ reimbursement structure
  - 7.4.6.3. Competitive scenario
  - 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Regulatory framework/ reimbursement structure
  - 7.4.7.3. Competitive scenario
  - 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Regulatory framework/ reimbursement structure
  - 7.4.8.3. Competitive scenario
  - 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. India
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Argentina
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework/ reimbursement structure
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework/ reimbursement structure
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
- 8.3.1. Key company market share analysis, 2024
- 8.3.2. AstraZeneca
  - 8.3.2.1. Company overview
  - 8.3.2.2. Financial performance
  - 8.3.2.3. Product benchmarking
  - 8.3.2.4. Strategic initiatives
- 8.3.3. GSK plc.
  - 8.3.3.1. Company overview
  - 8.3.3.2. Financial performance
  - 8.3.3.3. Product benchmarking
  - 8.3.3.4. Strategic initiatives
- 8.3.4. Pfizer Inc.
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Product benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5. Otsuka Holdings Co., Ltd
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Product benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6. Aurobindo Pharma
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Product benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7. Merck KGaA
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Product benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8. Jazz Pharmaceuticals, Inc.
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Product benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. Bionomics
  - 8.3.9.1. Company overview
  - 8.3.9.2. Financial performance
  - 8.3.9.3. Product benchmarking
  - 8.3.9.4. Strategic initiatives
- 8.3.10. Eli Lilly and Company
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Product benchmarking
  - 8.3.10.4. Strategic initiatives
- 8.3.11. Viatris Inc.
  - 8.3.11.1. Company overview
  - 8.3.11.2. Financial performance
  - 8.3.11.3. Product benchmarking
  - 8.3.11.4. Strategic initiatives

외상 후 스트레스 장애 치료 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 인구통계별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Post-traumatic Stress Disorder Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Demographics, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

외상 후 스트레스 장애 치료 시장의 성장과 동향

외상 후 스트레스 장애 치료 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 외상 후 스트레스 장애 치료 시장의 변수, 동향, 범위

제4장 외상 후 스트레스 장애 치료 시장 : 약물 종류별, 추정·동향 분석

제5장 외상 후 스트레스 장애 치료 시장 : 인구 통계별, 추정·동향 분석

제6장 외상 후 스트레스 장애 치료 시장 : 유통 채널별, 추정·동향 분석

제7장 외상 후 스트레스 장애 치료 시장 : 약물 종류, 인구 통계, 유통 채널에 의한 지역별, 추정·동향 분석